Related Experiment Video
Updated: Aug 5, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Sharing a flexible urethral sparing SBRT prostate RapidPlan model and quantifying plan quality via dosimetric
Jonathan Sackett1,2,3, Anthony Magliari4, Ryan Clark4
1Varian Medical Affairs, Siemens Healthineers, Palo Alto, CA, USA. jonathan.sackett@bannerhealth.com.
Purpose:
To develop and validate a Knowledge-Based Planning (KBP) model for prostate stereotactic body radiation therapy (SBRT) using a comprehensive dosimetric scorecard, aiming to improve plan quality and consistency while meeting the stringent criteria of the Adaptive Radiation Therapy Individualized Approach - Prostate (ARTIA) trial.
Methods:
A KBP model (ProstateSBRT-ARTIA-SIB40-36 Gy v1.1) was developed using RapidPlan v15.6 with 41 carefully selected prostate SBRT cases. A 35-metric dosimetric scorecard was created to guide the model development and evaluation process. The model was trained iteratively, with the scorecard used to tune optimization objectives and priorities. 10 independent cases were used for validation, testing both VMAT and IMRT beam arrangements.
Results:
The KBP model demonstrated significant improvement in plan quality compared to original clinical plans, with the average scorecard score increasing from 166.2/229 to 197.4/229 points. Validation cases showed consistent high-quality plan generation for both VMAT and IMRT techniques. The model exhibited flexibility in adapting to various dose levels and clinical scenarios, including the ability to scale urethral dose constraints.
Conclusion:
The dosimetric scorecard-guided KBP model for prostate SBRT demonstrates the potential to generate high-quality treatment plans efficiently and consistently. This approach offers a powerful method for translating complex clinical intent into actionable planning objectives, potentially improving treatment quality and reducing inter-planner variability. Future work will focus on expanding the model's capabilities, including boosting gross disease volumes and exploring direct optimization based on comprehensive dosimetric scorecards.
